TB-500 Fragment (17-23)

TB-500 Fragment (17-23), also known as fequesetide or Ac-LKKTETQ, is a synthetic heptapeptide (seven amino acid sequence) derived from the active actin-binding region of the naturally occurring peptide thymosin beta-4 (Tβ4). The name TB-500 Fragment (17-23) refers to amino acids 17 through 23 of the parent thymosin beta-4 molecule, representing the smallest portion that retains the protein’s critical actin-binding and biological activity. The complete amino acid sequence is: LEU-LYS-LYS-THR-GLU-THR-GLN (LKKTETQ), with N-terminal acetylation for enhanced stability. This synthetic fragment has a molecular weight of 846.97 g/mol and chemical formula C36H66N10O13. Thymosin beta-4 is a naturally occurring 43-amino acid peptide found in nearly all mammalian cells except red blood cells. It is one of the most abundant intracellular proteins and serves as the primary G-actin sequestering molecule. First identified in the thymus gland in the 1960s, it has been extensively studied for tissue repair, wound healing, and cellular migration. TB-500 Fragment (17-23) was developed as a research tool to isolate the specific actin-binding domain within the larger thymosin beta-4 molecule. Research has demonstrated that this seven- amino acid sequence retains actin-binding capability and can produce biological effects in controlled experimental conditions.

Important Note: Studies by Goldstein et al. (2012) identified multiple active sites within thymosin beta-4: fragments 1-4 (anti-inflammatory), 1-15 (anti-apoptotic and cytoprotective), and 17-23 (actin binding and migration). The 17-23 fragment provides only the actin-binding function while the full 43-amino acid molecule coordinates multiple biological pathways including anti-inflammatory signaling, anti-fibrotic activity, and sustained regenerative programs. For a full breakdown of each: TB-500 (LKKTETQ Fragment) vs. Thymosin Beta-4 (43aa)

How It Works

TB-500 Fragment (17-23) operates through actin binding and cytoskeletal modulation. The mechanisms described below are based on published research studies.

Actin Binding and Cellular Migration

The primary mechanism involves interaction with actin, a fundamental structural protein in eukaryotic cells. Actin exists as monomeric G-actin and polymerized F-actin filaments. TB-500 Fragment (17-23) binds to G-actin monomers through the LKKTETQ sequence, preventing spontaneous polymerization into F-actin filaments. This creates a pool of sequestered actin available for directed cell migration. Research by Philp et al. (2003) confirmed that this seven-amino acid sequence represents the minimal essential actin-binding motif. Peptides lacking any portion of this sequence lose biological activity, while those containing the complete LKKTETQ motif retain actin-binding capability.

Angiogenesis Promotion

TB-500 Fragment (17-23) can stimulate angiogenesis (new blood vessel formation) through actin-dependent mechanisms. Studies by Philp et al. (2003) demonstrated that the fragment and full-length thymosin beta-4 display similar angiogenic activity at nanomolar concentrations in short-term in vitro assays using human umbilical vein endothelial cells and chick aortic arch vessel sprouting models. The mechanism involves endothelial cell migration and adhesion to extracellular matrix components. Research shows the fragment promotes tubule formation at concentrations around 50 nM. Soluble actin can inhibit these angiogenic effects, confirming that biological activity depends on intact actin-binding capability.

Wound Healing Support

Animal studies demonstrate that TB-500 Fragment (17-23) can accelerate wound healing under controlled experimental conditions. Research in diabetic mice and aged mice by Philp et al. (2003) showed that the fragment promoted wound repair with increased wound contraction, enhanced collagen deposition, and improved keratinocyte migration when administered in optimized dosing regimens. The fragment promotes migration of various cell types essential for tissue repair, including keratinocytes (skin cells), fibroblasts (connective tissue cells), and endothelial cells (blood vessel cells). It also stimulates production of extracellular matrix proteins including laminin-332, fibronectin, and collagen.

Benefits

TB-500 Fragment (17-23) has been studied in laboratory and preclinical settings. The following benefits have been documented in research models:

Actin-Mediated Cell Migration

Research demonstrates the fragment promotes cell migration through direct actin binding:

• Enhanced migration of keratinocytes, fibroblasts, and endothelial cells in vitro
• Comparable activity to full-length thymosin beta-4 in 4-24 hour migration assays
• Promotion of cellular recruitment to wound edges in experimental models

Wound Healing Acceleration

Animal studies have shown wound healing benefits:

• In diabetic mice, the fragment promoted wound repair with increased wound contracture and

collagen deposition

• In aged mice, accelerated wound healing with improved keratinocyte migration
• Effects were comparable to full-length thymosin beta-4 in these specific experimental

conditions

• Both subcutaneous and hydrogel formulations showed efficacy

Research Context: These animal studies used controlled dosing regimens optimized for research settings. The practical translation of these findings to human applications requires consideration of the fragment’s pharmacokinetic properties.

Angiogenic Activity

Research demonstrates angiogenic effects through:

• Stimulation of endothelial cell migration and tubule formation
• Enhanced endothelial cell adhesion to matrix components
• Promotion of aortic ring sprouting in experimental models
• Activity at nanomolar concentrations (approximately 50 nM)

Collagen Synthesis

Studies by Maquart et al. (1993) examining thymosin beta-4 in rat wound healing models found increased collagen synthesis at wound sites. The fragment stimulates collagen production and promotes organized collagen deposition, which contributes to tissue repair.

What the Science Shows

Philp et al. (2003) Published in FASEB Journal. This study identified the actin-binding site on thymosin beta-4 and demonstrated its role in angiogenic activity. Key findings:

• The seven amino acid LKKTETQ motif is essential for angiogenic activity
• TB-500 Fragment (17-23) and full-length thymosin beta-4 display similar activity at

approximately 50 nM in short-term in vitro assays

• Peptides lacking any portion of the actin-binding motif were inactive
• The fragment promotes endothelial cell migration, adhesion, and vessel sprouting
• Soluble actin inhibits angiogenic activity, confirming mechanism depends on actin binding

Philp et al. (2003) Published in Wound Repair and Regeneration. This study examined thymosin beta-4 and its synthetic actin-binding domain in diabetic and aged mice. Key findings:

• TB-500 Fragment (17-23) promoted wound repair in aged animals under controlled

experimental conditions

• In diabetic mice, significantly increased wound contracture and collagen deposition
• In aged mice, accelerated wound healing with increased keratinocyte migration
• Both PBS and hydrogel formulations showed similar efficacy

Goldstein et al. (2012) Published in Expert Opinion on Biological Therapy. Comprehensive review of thymosin beta-4 as a multi-functional regenerative peptide. Key findings:

• Thymosin beta-4 promotes cell migration, angiogenesis, and wound healing
• Multiple active sites identified within the full molecule:

– Fragments 1-4 (anti-inflammatory) – Fragments 1-15 (anti-apoptotic and cytoprotective) – Fragments 17-23 (migration and actin binding)

• Thymosin beta-4 is naturally present at high concentrations in wound fluid (13 μg/mL)

Sources:

• Philp D, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J.

2003. https://pubmed.ncbi.nlm.nih.gov/14500546/

• Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain

promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003. https://pubmed.ncbi.nlm.nih.gov/12581423/

• Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol

Ther. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/

• Maquart FX, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-

copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993. https://pubmed.ncbi.nlm.nih.gov/8227361/

Dosing Protocol

TB-500 Fragment (17-23) is available in injectable form as lyophilized (freeze-dried) powder requiring reconstitution. The following protocols are based on research literature and community-reported practices. There are no FDA-approved dosing guidelines for human use. Injectable Protocol (Subcutaneous or Intramuscular) Standard Loading Protocol:

• Dose: 2 to 2.5 mg per injection
• Frequency: Every other day (3 to 4 times per week)
• Total weekly dose: 6 to 10 mg
• Duration: 4 to 8 weeks

Maintenance Protocol:

• Dose: 2 to 5 mg per week
• Frequency: Once or twice weekly
• Duration: Ongoing as needed

Conservative Protocol:

• Dose: 0.5 to 1 mg per day
• Frequency: Daily
• Total weekly dose: 3.5 to 7 mg
• Duration: 8 to 12 weeks

Note on Pharmacokinetics: While specific pharmacokinetic studies on TB-500 Fragment are limited, peptides of this size (7 amino acids, approximately 847-889 Da) generally have short half-lives in circulation. Research on similar small peptides indicates plasma half-lives typically measured in minutes to hours rather than days. The biological effects may persist longer than the circulating half-life because the peptide can trigger cellular responses that continue after the peptide itself has been metabolized. TB-500 Fragment (17-23) demonstrates rapid systemic distribution following administration. While some users report preferential effects when injecting near injury sites (intramuscular), subcutaneous administration provides effective systemic delivery to injured tissues throughout the body.

Draw Volumes by Vial Size

10 mg Vial with 2 mL Bacteriostatic Water (5 mg/mL concentration) 0.5 mg dose = 0.10 mL = 10 units 1.0 mg dose = 0.20 mL = 20 units 2.0 mg dose = 0.40 mL = 40 units 2.5 mg dose = 0.50 mL = 50 units Vial duration at 2 mg every other day (3.5×/week): approximately 5 weeks 10 mg Vial with 1 mL Bacteriostatic Water (10 mg/mL concentration) 0.5 mg dose = 0.05 mL = 5 units 1.0 mg dose = 0.10 mL = 10 units 2.0 mg dose = 0.20 mL = 20 units 2.5 mg dose = 0.25 mL = 25 units Note: The more concentrated solution (1 mL reconstitution) results in smaller injection volumes but requires more precise measurement. A 30-unit or 50-unit insulin syringe is recommended for doses under 10 units.

Reconstitution

Materials Needed:

• TB-500 Fragment (17-23) vial (lyophilized powder)
• Bacteriostatic water or sterile water
• Sterile syringe for reconstitution
• Alcohol swabs

Instructions: 1. Wipe the TB-500 Fragment vial stopper and bacteriostatic water vial with alcohol swabs 2. Draw 1 to 2 mL of bacteriostatic water (depending on desired concentration) 3. Insert needle through rubber stopper at an angle 4. Let water trickle slowly down the inside wall of the vial 5. Do not inject directly onto the powder or shake vigorously 6. Gently swirl until fully dissolved 7. The solution should be clear and colorless 8. If solution contains particles or cloudiness, do not use

Side Effects

TB-500 Fragment (17-23) has demonstrated a favorable safety profile in animal studies. Clinical studies with full-length thymosin beta-4 have shown good tolerability at doses far exceeding typical TB-500 Fragment protocols.

Common Side Effects

Injection site reactions:

• Mild redness, swelling, or tenderness at injection site
• Temporary irritation (usually resolves within hours to days)
• Slight bruising (less common)

Systemic effects (less common):

• Mild headache (particularly during loading phase)
• Temporary lethargy or fatigue
• Slight water retention or bloating (when stacked with other peptides)

Safety Studies

A randomized controlled trial in 40 healthy adults evaluated the safety of intravenously administered thymosin beta-4 at doses ranging from 42 mg to 1,260 mg. The study found that thymosin beta-4 was well-tolerated with minimal risk for toxicity. Adverse events were uncommon and only mild or moderate in nature when they occurred. For context, typical TB-500 Fragment (17-23) dosing protocols use 2 to 10 mg per week, which is substantially lower than the doses evaluated in this safety study.

Strategies to Minimize Side Effects

• Rotate injection sites (never use the same location twice in a row)
• Start with lower doses and gradually increase to assess tolerance
• Ensure proper reconstitution technique to avoid contamination
• Stay well-hydrated, especially during loading phases
• Consider combining with BPC-157 in peptide blends, which may reduce local irritation

Contraindications and Precautions

Do Not Use If You Have:

• Active cancer or tumors (theoretical concern about pro-angiogenic effects)
• Known hypersensitivity to TB-500 Fragment (17-23) or thymosin beta-4
• Active malignancy or recent history of cancer without oncologist approval

Use Caution With:

• Pregnancy or breastfeeding (no safety data available)
• Active autoimmune disorders
• Severe liver or kidney impairment
• Blood thinning medications

Theoretical Concerns

Cancer risk: Because TB-500 Fragment (17-23) promotes angiogenesis and cellular proliferation, there is theoretical concern that it could support tumor growth or metastasis in individuals with undiagnosed cancer. This concern is based on mechanism rather than observed clinical events, but caution is warranted. Drug Interactions: Limited data are available on drug interactions with TB-500 Fragment (17- 23). Unlike many small molecule drugs, the fragment does not undergo hepatic metabolism via cytochrome P450 enzymes, which reduces the likelihood of metabolic drug interactions. Consult a qualified healthcare provider before combining TB-500 Fragment (17-23) with other medications or therapeutic peptides.

Regulatory Status

United States: TB-500 Fragment (17-23) is not approved by the FDA for any medical use in humans. It is available as a research chemical from peptide suppliers. In 2023, the FDA classified many compounding peptides as Category 2 bulk drug substances, affecting availability through compounding pharmacies. WADA Status: TB-500 Fragment (17-23) and all thymosin beta-4 derivatives are prohibited by the World Anti- Doping Agency (WADA) under the S0 category (Non-Approved Substances) and S2 category (Growth Factors and Growth Factor Modulators). Use is banned at all times, both in and out of competition, for all athletes subject to WADA regulations.

TB-500 Fragment (17-23) vs Other Healing Peptides

TB-500 Fragment (17-23) works through actin-binding mechanisms compared to other commonly used healing peptides: TB-500 Fragment (17-23) Excels At:

• Promoting cellular migration through actin binding
• Supporting angiogenesis in experimental models
• Modulating actin dynamics for cell structure and movement

BPC-157 Excels At:

• Acute injury healing and tissue protection
• Gastrointestinal healing and protection
• Reducing inflammation rapidly
• Tendon and ligament repair

Combination Approach

Many users combine TB-500 Fragment (17-23) with BPC-157 for comprehensive healing support. This combination addresses multiple healing pathways, with TB-500 Fragment providing actin-mediated cellular migration support and BPC-157 providing targeted tissue protection. The peptides work through complementary mechanisms.

Success Tips

Expect Gradual Results

TB-500 Fragment (17-23) works through biological tissue repair mechanisms, which take time. Typical timeline based on anecdotal reports:

• First 1-2 weeks: May notice reduced inflammation, improved flexibility
• 2-4 weeks: Progressive improvement in injury symptoms
• 4-8 weeks: Significant tissue repair, improved strength and function
• 8-12 weeks: Maximum benefits

Choose the Right Administration Approach

Subcutaneous injection: Most common, provides systemic distribution to injured tissues throughout the body. Intramuscular injection: Sometimes preferred for site-specific targeting near injuries, though systemic distribution still occurs. Common injection sites for subcutaneous administration include abdominal fat, outer thigh, or love handle region. For intramuscular injection, areas near the affected muscle or joint can be used.

Rotate Injection Sites

Never use the same injection site twice in a row. Rotation prevents tissue irritation and ensures consistent absorption.

Support Healing with Proper Recovery

TB-500 Fragment (17-23) enhances the body’s natural healing processes but works best when combined with:

• Adequate rest and sleep (7-9 hours per night)
• Proper nutrition with sufficient protein (1.2-2.0 g/kg body weight)
• Hydration (especially important for collagen synthesis)
• Appropriate physical therapy or rehabilitation exercises
• Gradual return to activity

Storage and Handling

Before Reconstitution:

• Store lyophilized (powder) vials at -20°C (-4°F) or below for long-term storage
• Can be stored at 2 to 8°C (35 to 46°F) for shorter periods
• Protect from light and moisture
• Stable for months to years when stored properly

After Reconstitution:

• Refrigerate at 2 to 8°C (35 to 46°F)
• Use within 30 days for optimal potency
• Do not freeze after reconstitution

• Keep away from direct light
• Discard if solution becomes cloudy or contains particles

Product Source: Pharma-grade research peptides that are third-party tested. www.Biolongevitylabs.store – use code “JFDISCOUNT” for 15% off

Frequently Asked Questions

What is the difference between TB-500 Fragment (17-23) and full-length thymosin beta-4? TB-500 Fragment (17-23) is a seven amino acid synthetic peptide (LKKTETQ) that represents the actin-binding domain of the full 43-amino acid thymosin beta-4 protein. Research by Goldstein et al. (2012) identified that thymosin beta-4 contains multiple active sites: fragments 1- 4 provide anti-inflammatory activity, fragments 1-15 provide anti-apoptotic and cytoprotective effects, and fragments 17-23 provide actin binding and cell migration. The fragment isolates one specific function while the full molecule coordinates multiple biological pathways. For a full breakdown of each: TB-500 (LKKTETQ Fragment) vs. Thymosin Beta-4 (43aa) How long until I see results from TB-500 Fragment (17-23)? Based on anecdotal reports, initial improvements such as reduced inflammation and improved flexibility may appear within 1-2 weeks. More significant tissue repair and functional improvements typically become apparent after 4-8 weeks of consistent use. The timeline varies based on injury severity, individual healing capacity, and adherence to protocols. Should I inject TB-500 Fragment (17-23) directly into the injured area? TB-500 Fragment (17-23) distributes systemically after injection regardless of injection site. While some users prefer intramuscular injection near affected areas, subcutaneous injection at any site provides effective systemic delivery. Both routes are commonly used.

Can I stack TB-500 Fragment (17-23) with BPC-157?

Yes. This combination is popular for comprehensive healing support. TB-500 Fragment (17-23) provides actin-mediated cellular migration support while BPC-157 offers targeted tissue protection and rapid inflammation reduction. The peptides work through complementary mechanisms. What is the half-life of TB-500 Fragment (17-23)? While specific pharmacokinetic studies on TB-500 Fragment (17-23) are limited, peptides of this size (7 amino acids, approximately 847-889 Da) generally have short half-lives in circulation. Research on peptide-based drugs indicates plasma half-lives are often measured in minutes to hours. The biological effects may persist longer than the circulating half-life because the peptide can trigger cellular responses that continue after metabolism. Is TB-500 Fragment (17-23) safe for long-term use? Long-term safety data in humans is limited. Most protocols use TB-500 Fragment (17-23) for 4- 12 week cycles. Safety studies with full-length thymosin beta-4 have shown good tolerability at high doses for short durations, but data on extended use is lacking. Consult a qualified healthcare provider before considering long-term use.

References

1. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. 2. Philp D, Badamchian M, Scheremeta B, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. https://pubmed.ncbi.nlm.nih.gov/12581423/ 3. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/ 4. Maquart FX, Pickart L, Laurent M, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-2376. https://pubmed.ncbi.nlm.nih.gov/8227361/ 5. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151. 6. Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. https://pubmed.ncbi.nlm.nih.gov/20536467/